BGM (BGM Group Limited) EV/EBITDA Multiple

Corporate emblem and logo of BGM Group Ltd (BGM)

The average predictability of cash flows for BGM Group Ltd is based on patents, which correlates with the company's EV/EBITDA ratio. The current level of 0.00 determines this parameter level. The management's scientific expertise in drug development, combined with a protected market niche in the therapy of rare pathologies, provides the company with resilience against price competition and effective asset management.

BGM Group Corp - BGM Enterprise Value to Operating Income Before Depreciation (period 11/23/2025 - 11/14/2026)

Financial and market metric breakdowns for BGM Group (BGM)

- stock price and consensus target price:
Stock Quotes BGM Group Limited|BGM - Forecast Levels Chart
- business market valuation indicators:
Market Capitalization BGM Group Corp|BGM - Total Enterprise Value
- issuer book value statistics:
Book Value per Share BGM Group|BGM - Accounting Capitalization|Market Cap to Net Assets Ratio bgm.ltd|BGM - Aggregate Asset Value
- debt and liquidity data:
Debt to Equity BGM Group Ltd|BGM - Long-Term Liabilities to Equity|Short-Term Debt to Capital BGM Group Ltd|BGM - Aggregate Debt Obligations|Debts to Book Capitalization BGM Group|BGM - Company Long-Term Debts|Company Short-Term Debt BGM Group|Quick Liquidity bgm.ltd
- financial results and valuation multiples details:
BGM - Net Income|Projected Future Earnings BGM Group Ltd|BGM - P/E Multiple|Forward P/E Multiple BGM Group Corp|BGM - Price/Earnings to Growth Ratio|EV/EBITDA Multiple BGM Group Ltd|BGM - Operating profit before depreciation charges|Earnings per share for the last twelve months BGM Group|BGM - Net earnings per share for the last 12 months|Year-over-year net earnings per share growth for the last 12 months bgm.ltd|BGM - Earnings per share increase in current year|Earnings growth forecast for next year BGM Group Ltd
- sales and revenue indicators:
BGM - Company Total Sales Volume|Company Projected Revenue BGM Group Ltd|BGM - Market Capitalization-to-Revenue Ratio|Price-to-Projected Revenue Ratio BGM Group Corp
Summary company analysis:BGM Group Ltd BGM
Original product of bgm.ltd

Analyzing the resilience of BGM Group Ltd (BGM) to market shocks requires accounting for the capital intensity of biopharmaceutical production, where AI implementation optimizes raw material costs. The trajectory of the company's EV/EBITDA ratio reflects the relationship between total enterprise value and operating profit before interest, taxes, depreciation, and amortization, allowing investors to compare market pricing with actual asset efficiency to identify whether the valuation is undervalued or overheated.

Competitors of BGM Group Ltd

EV/EBITDA Multiple VRTX (vrtx.com)|Total Company Value to Operating Income Before Depreciation Ratio Alnylam (ALNY)|INSM: Enterprise Value to EBITDA Ratio|Company Value to Operating Income Before Depreciation Ratio UTHR|BMRN: EV/EBITDA Multiple|Company Value to EBITDA BridgeBio Pharma Inc (BBIO)|COGT (Cogent Biosciences, Inc.) - EV/EBITDA Multiple|Enterprise Value to Operating Income Before Depreciation XERS (Xeris Biopharma Holdings)|Enterprise Value to EBITDA Ratio KROS (Keros Therapeutics, Inc.)|ARCT (Arcturus Therapeutics Inc) - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Eton Pharmaceuticals, Inc. ETON|KMDA (Kamada Corp) - Company Value to Operating Income Before Depreciation Ratio|Fulcrum Therapeutics - EV/EBITDA Multiple|Business Value to Operating Income Before Depreciation ABEO (abeonatherapeutics.com)|MREO: EV/EBITDA Multiple|Protalix BioTherapeutics Inc. - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization pliantrx.com|APLT: Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization aileronrx.com (RNTX)|Enterprise Value to EBITDA Ratio Gelteq GELS|EV/EBITDA Multiple AYTU (Aytu BioPharma Inc)|EV/EBITDA Multiple Chemomab CMMB|SRXH - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio PLRZ|AEZS: EV/EBITDA Multiple|Company Value to EBITDA Cyclo Therapeutics (CYTH)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Inozyme Pharma Inc.|Enterprise Value to Operating Income Before Depreciation RPHM (Reneo Pharmaceuticals, Inc.)|EV/EBITDA Multiple CSCI